Type 2 diabetes in children and adolescents

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 3, 2010, Pages 393-406

  Amed, Shazhan ^a   Daneman, Denis ^b   Mahmud, Farid H ^b   Hamilton, Jill ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

cell function; Insulin resistance; Obesity; Pediatrics; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN SENSITIZING AGENT; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE;

ABDOMINAL OBESITY; ADOLESCENT; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES EDUCATION; DIABETIC DIET; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETOGENESIS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; GLYCEMIC CONTROL; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN DEFICIENCY; INSULIN HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KETOGENIC DIET; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MATERNAL DIABETES MELLITUS; METABOLIC SYNDROME X; MICROALBUMINURIA; MOLECULAR GENETICS; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRENATAL PERIOD; PREVALENCE; PUBLIC HEALTH PROBLEM; REVIEW; RISK FACTOR; ROUX Y ANASTOMOSIS; SIDE EFFECT; STOMACH BYPASS; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; AGE FACTORS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; GREAT BRITAIN; HEALTH EDUCATION; HUMANS; INSULIN RESISTANCE; MALE; NEEDS ASSESSMENT; NORTH AMERICA; OBESITY; PREVALENCE; RISK FACTORS; SEX FACTORS;

EID: 77949457243     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.15     Document Type: Review

References (125)

1. Nadeau K, Dabelea D. Epidemiology of Type 2 diabetes in children and adolescents. Endocr. Res. 33(1-2), 35-58 (2008).
2. Dabelea D, Hanson RL, Bennett PH, Roumain J, Knowler WC, Pettitt DJ. Increasing prevalence of Type II diabetes in American Indian children. Diabetologia 41(8), 904-910 (1998).
3. Dean HJ, Young TK, Flett B, Wood-Steiman P. Screening for Type-2 diabetes in aboriginal children in northern Canada. Lancet 352(9139), 1523-1524 (1998).
4. Fagot-Campagna A, Saaddine JB, Flegal KM, Beckles GL. Diabetes impaired fasting glucose, and elevated HbA1c in U.S. adolescents: the Third National Health and Nutrition Examination survey. Diabetes Care 24(5), 834-837 (2001).
5. Duncan GE. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination survey, 1999-2002. Arch. Pediatr. Adolesc. Med. 160(5), 523-528 (2006).
6. Liese AD, D'Agostino RB Jr, Hamman RF et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 118(4), 1510-1518 (2006).
7. Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM. National surveillance for Type 2 diabetes mellitus in Taiwanese children. JAMA 290(10), 1345-1350 (2003).
8. Dolan LM, Bean J, D'Alessio D et al. Frequency of abnormal carbohydrate metabolism and diabetes in a population-based screening of adolescents. J. Pediatr. 146(6), 751-758 (2005).
9. Baranowski T, Cooper DM, Harrell J et al. Presence of diabetes risk factors in a large U.S. eighth-grade cohort. Diabetes Care 29(2), 212-217 (2006).
10. Bar Dayan Y, Elishkevits K, Grotto I et al. The prevalence of obesity and associated morbidity among 17-year-old Israeli conscripts. Public Health 119(5), 385-389 (2005).
11. Lipton R, Keenan H, Onyemere KU, Freels S. Incidence and onset features of diabetes in African-American and Latino children in Chicago, 1985-1994. Diabetes Metab. Res. Rev. 18(2), 135-142 (2002).
12. Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J. Pediatr. 128(5 Pt 1), 608-615 (1996).
13. Zdravkovic V, Daneman D, Hamilton J. Presentation and course of Type 2 diabetes in youth in a large multi-ethnic city. Diabet. Med. 21(10), 1144-1148 (2004).
14. Macaluso CJ, Bauer UE, Deeb LC et al. Type 2 diabetes mellitus among Florida children and adolescents, 1994 through 1998. Public Health Rep. 117(4), 373-379 (2002).
15. Kitagawa T, Mano T, Fujita H. The epidemiology of childhood diabetes mellitus in Tokyo metropolitan area. Tohoku J. Exp. Med. 141(Suppl.), 171-179 (1983).
16. Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T. Annual incidence and clinical characteristics of Type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 28(8), 1876-1881 (2005).
17. Urakami T, Morimoto S, Nitadori Y, Harada K, Owada M, Kitagawa T. Urine glucose screening program at schools in Japan to detect children with diabetes and its outcome-incidence and clinical characteristics of childhood Type 2 diabetes in Japan. Pediatr. Res. 61(2), 141-145 (2007).
18. Craig ME, Femia G, Broyda V, Lloyd M, Howard NJ. Type 2 diabetes in indigenous and non-indigenous children and adolescents in New South Wales. Med. J. Aust. 186(10), 497-499 (2007).
19. Schober E, Waldhoer T, Rami B, Hofer S. Incidence and time trend of Type 1 and Type 2 diabetes in Austrian children 1999-2007. J. Pediatr. 155(2), 190-193 e191 (2009).
20. Haines L, Wan KC, Lynn R, Barrett TG, Shield JP. Rising incidence of Type 2 diabetes in children in the U.K. Diabetes Care 30(5), 1097-1101 (2007).
21. Amed S, Dean HJ, Panagiotopoulos D et al. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in canadian children: a prospective national surveillance study. Diabetes Care (2010) (Epub ahead of print).
22. Dabelea D, Bell RA, D'Agostino RB Jr et al. Incidence of diabetes in youth in the United States. JAMA 297(24), 2716-2724 (2007).
23. Dabelea D, DeGroat J, Sorrelman C et al. Diabetes in Navajo youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 32(Suppl. 2), S141-S147 (2009).
24. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S. Youth Type 2 diabetes: insulin resistance, b-cell failure, or both? Diabetes Care 28(3), 638-644 (2005).
25. Druet C, Tubiana-Rufi N, Chevenne D, Rigal O, Polak M, Levy-Marchal C. Characterization of insulin secretion and resistance in Type 2 diabetes of adolescents. J. Clin. Endocrinol. Metab. 91(2), 401-404 (2006).
26. Elder DA, Prigeon RL, Wadwa RP, Dolan LM, D'Alessio DA. b-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J. Clin. Endocrinol. Metab. 91(1), 185-191 (2006).
27. Weiss R. Impaired glucose tolerance and risk factors for progression to Type 2 diabetes in youth. Pediatr. Diabetes 8(Suppl. 9), 70-75 (2007).
28. Trout KK, Homko C, Tkacs NC. Methods of measuring insulin sensitivity. Biol. Res. Nurs. 8(4), 305-318 (2007).
29. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 50(11), 2444-2450 (2001).
30. Moran A, Jacobs DR Jr, Steinberger J et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 48(10), 2039-2044 (1999).
31. Caprio S, Cline G, Boulware S et al. Effects of puberty and diabetes on metabolism of insulin-sensitive fuels. Am. J. Physiol. 266(6 Pt 1), E885-E891 (1994).
32. Moran A, Jacobs DR Jr, Steinberger J et al. Association between the insulin resistance of puberty and the insulin-like growth factor-I/ growth hormone axis. J. Clin. Endocrinol. Metab. 87(10), 4817-4820 (2002).
33. Libman IM, Arslanian SA. Prevention and treatment of Type 2 diabetes in youth. Horm. Res. 67(1), 22-34 (2007).
34. Bjorntorp P, Rosmond R. Visceral obesity and diabetes. Drugs 58(Suppl. 1), 13-18; discussion 75-82 (1999).
35. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116(7), 1784-1792 (2006).
36. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29(24), 2959-2971 (2008).
37. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of Type 2 diabetes: a systematic review and meta-analysis. JAMA 302(2), 179-188 (2009).
38. Weiss R, Taksali SE, Dufour S et al. The 'obese insulin-sensitive' adolescent: importance of adiponectin and lipid partitioning. J. Clin. Endocrinol. Metab. 90(6), 3731-3737 (2005).
39. Bottner A, Kratzsch J, Muller G et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J. Clin. Endocrinol. Metab. 89(8), 4053-4061 (2004).
40. Bacha F, Gungor N, Arslanian SA. Measures of b-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J. Pediatr. 152(5), 618-621 (2008).
41. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. b-cell function across the spectrum of glucose tolerance in obese youth. Diabetes 54(6), 1735-1743 (2005).
42. Rosenbaum M, Nonas C, Horlick M et al. b-cell function and insulin sensitivity in early adolescence: association with body fatness and family history of Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89(11), 5469-5476 (2004).
43. Tfayli H, Bacha F, Gungor N, Arslanian S. Phenotypic Type 2 diabetes in obese youth: insulin sensitivity and secretion in islet cell antibody-negative versus -positive patients. Diabetes 58(3), 738-744 (2009).
44. Goran MI, Lane C, Toledo-Corral C, Weigensberg MJ. Persistence of pre-diabetes in overweight and obese Hispanic children: association with progressive insulin resistance, poor b-cell function, and increasing visceral fat. Diabetes 57(11), 3007-3012 (2008).
45. Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care 28(4), 902-909 (2005).
46. Edelstein SL, Knowler WC, Bain RP et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46(4), 701-710 (1997).
47. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC; UK Prospective Diabetes Study (UKPDS) group. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet. Med. 15(4), 297-303 (1998).
48. Saad R, Gungor N, Arslanian S. Progression from normal glucose tolerance to Type 2 diabetes in a young girl: longitudinal changes in insulin sensitivity and secretion assessed by the clamp technique and surrogate estimates. Pediatr. Diabetes 6(2), 95-99 (2005).
49. Weiss R, Dufour S, Taksali SE et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362(9388), 951-957 (2003).
50. Cali AM, Caprio S. Obesity in children and adolescents. J. Clin. Endocrinol. Metab. 93(11 Suppl. 1), S31-S36 (2008).
51. Canadian Diabetes Association 2008. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can. J. Diabetes 32(Suppl. 1), S162-S167 (2008).
52. Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ. ISPAD Clinical Practice Consensus Guideline 2006-2007. Type 2 diabetes mellitus in the child and adolescent. Pediatr. Diabetes 9(5), 512-526 (2008).
53. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int. J. Pediatr. Obes. 1(1), 11-25 (2006).
54. Haslam DW, James WP. Obesity. Lancet 366(9492), 1197-1209 (2005).
55. Clarke WR, Lauer RM. Does childhood obesity track into adulthood? Crit. Rev. Food Sci. Nutr. 33(4-5), 423-430 (1993).
56. Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care 29(11), 2427-2432 (2006).
57. Weiss R, Dziura J, Burgert TS et al. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 350(23), 2362-2374 (2004).
58. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart study. N. Engl. J. Med. 338(23), 1650-1656 (1998).
59. Silverstein JH, Rosenbloom AL. Type 2 diabetes in children. Curr. Diab. Rep. 1(1), 19-27 (2001).
60. Magge SN, Stettler N, Jawad AF, Levitt Katz LE. Increased prevalence of abnormal glucose tolerance among obese siblings of children with Type 2 diabetes. J. Pediatr. 154(4), 562-566 e561 (2009).
61. Arslanian SA, Bacha F, Saad R, Gungor N. Family history of Type 2 diabetes is associated with decreased insulin sensitivity and an impaired balance between insulin sensitivity and insulin secretion in white youth. Diabetes Care 28(1), 115-119 (2005).
62. Groop LC, Tuomi T. Non-insulin-dependent diabetes mellitus - a collision between thrifty genes and an affluent society. Ann. Med. 29(1), 37-53 (1997).
63. Stolerman ES, Florez JC. Genomics of Type 2 diabetes mellitus: implications for the clinician. Nat. Rev. Endocrinol. 5(8), 429-436 (2009).
64. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor g agonists. J. Clin. Invest. 106(4), 467-472 (2000).
65. Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARg Pro12Ala polymorphism is associated with decreased risk of Type 2 diabetes. Nat. Genet. 26(1), 76-80 (2000).
66. Gloyn AL, Weedon MN, Owen KR et al. Large-scale association studies of variants in genes encoding the pancreatic b-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with Type 2 diabetes. Diabetes 52(2), 568-572 (2003).
67. Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat. Genet. 38(3), 320-323 (2006).
68. Zeggini E, McCarthy MI. TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia 50(1), 1-4 (2007).
69. Groves CJ, Zeggini E, Minton J et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a Type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 55(9), 2640-2644 (2006).
70. Korner A, Berndt J, Stumvoll M, Kiess W, Kovacs P. TCF7L2 gene polymorphisms confer an increased risk for early impairment of glucose metabolism and increased height in obese children. J. Clin. Endocrinol. Metab. 92(5), 1956-1960 (2007).
71. Sellers EA, Triggs-Raine B, Rockman-Greenberg C, Dean HJ. The prevalence of the HNF-1a G319S mutation in Canadian aboriginal youth with Type 2 diabetes. Diabetes Care 25(12), 2202-2206 (2002).
72. Arslanian SA. Metabolic differences between Caucasian and African-American children and the relationship to Type 2 diabetes mellitus. J. Pediatr. Endocrinol. Metab. 15(Suppl. 1), 509-517 (2002).
73. Weiss R, Dziura JD, Burgert TS, Taksali SE, Tamborlane WV, Caprio S. Ethnic differences in b cell adaptation to insulin resistance in obese children and adolescents. Diabetologia 49(3), 571-579 (2006).
74. Weiss R, Kaufman FR. Metabolic complications of childhood obesity: identifying and mitigating the risk. Diabetes Care 31(Suppl. 2), S310-S316 (2008).
75. Saad RJ, Danadian K, Lewy V, Arslanian SA. Insulin resistance of puberty in African-American children: lack of a compensatory increase in insulin secretion. Pediatr. Diabetes 3(1), 4-9 (2002).
76. Steinberger J, Daniels SR, Eckel RH et al. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 119(4), 628-647 (2009).
77. Bao W, Srinivasan SR, Berenson GS; the Bogalusa Heart study. Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. Circulation 93(1), 54-59 (1996).
78. Sinaiko AR, Steinberger J, Moran A et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation 111(15), 1985-1991 (2005).
79. Simeoni U, Barker DJ. Offspring of diabetic pregnancy: long-term outcomes. Semin. Fetal Neonatal Med. 14(2), 119-124 (2009).
80. Plagemann A. A matter of insulin: developmental programming of body weight regulation. J. Matern. Fetal Neonatal Med. 21(3), 143-148 (2008).
81. Silverman BL, Rizzo T, Green OC et al. Long-term prospective evaluation of offspring of diabetic mothers. Diabetes 40(Suppl. 2), 121-125 (1991).
82. Pettitt DJ, Bennett PH, Saad MF et al. Abnormal glucose tolerance during pregnancy in Pima Indian women. Long-term effects on offspring. Diabetes 40(Suppl. 2), 126-130 (1991).
83. Dabelea D, Mayer-Davis EJ, Lamichhane AP et al. Association of intrauterine exposure to maternal diabetes and obesity with Type 2 diabetes in youth: the SEARCH Case-Control study. Diabetes Care 31(7), 1422-1426 (2008).
84. Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for Type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. J. Pediatr. Endocrinol. Metab. 14(8), 1085-1091 (2001).
85. Bhargava SK, Sachdev HS, Fall CH et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N. Engl. J. Med. 350(9), 865-875 (2004).
86. Eriksson JG, Forsen T, Tuomilehto J, Osmond C, Barker DJ. Early adiposity rebound in childhood and risk of Type 2 diabetes in adult life. Diabetologia 46(2), 190-194 (2003).
87. Leunissen RW, Kerkhof GF, Stijnen T, Hokken-Koelega A. Timing and tempo of first-year rapid growth in relation to cardiovascular and metabolic risk profile in early adulthood. JAMA 301(21), 2234-2242 (2009).
88. Pinhas-Hamiel O, Zeitler P. Clinical presentation and treatment of Type 2 diabetes in children. Pediatr. Diabetes 8(Suppl. 9), 16-27 (2007).
89. Pinhas-Hamiel O, Standiford D, Hamiel D, Dolan LM, Cohen R, Zeitler PS. The Type 2 family: a setting for development and treatment of adolescent Type 2 diabetes mellitus. Arch. Pediatr. Adolesc. Med. 153(10), 1063-1067 (1999).
90. No authors listed. Type 2 diabetes in children and adolescents. American Diabetes Association. Pediatrics 105(3 Pt 1), 671-680 (2000).
91. Libman IM, Barinas-Mitchell E, Bartucci A, Robertson R, Arslanian S. Reproducibility of the oral glucose tolerance test in overweight children. J. Clin. Endocrinol. Metab. 93(11), 4231-4237 (2008).
92. Nader NS, Kumar S. Type 2 diabetes mellitus in children and adolescents: where do we stand with drug treatment and behavioral management? Curr. Diab. Rep. 8(5), 383-388 (2008).
93. Willi SM, Martin K, Datko FM, Brant BP. Treatment of Type 2 diabetes in childhood using a very-low-calorie diet. Diabetes Care 27(2), 348-353 (2004).
94. Sondike SB, Copperman N, Jacobson MS. Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factor in overweight adolescents. J. Pediatr. 142(3), 253-258 (2003).
95. Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS. A reduced-glycemic load diet in the treatment of adolescent obesity. Arch. Pediatr. Adolesc. Med. 157(8), 773-779 (2003).
96. Giannini C, de Giorgis T, Mohn A, Chiarelli F. Role of physical exercise in children and adolescents with diabetes mellitus. J. Pediatr. Endocrinol. Metab. 20(2), 173-184 (2007).
97. Bell LM, Watts K, Siafarikas A et al. Exercise alone reduces insulin resistance in obese children independently of changes in body composition. J. Clin. Endocrinol. Metab. 92(11), 4230-4235 (2007).
98. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J. Pediatr. Endocrinol. Metab. 15(Suppl. 2), 737-744 (2002).
99. Sellers EA, Dean HJ. Short-term insulin therapy in adolescents with Type 2 diabetes mellitus. J. Pediatr. Endocrinol. Metab. 17(11), 1561-1564 (2004).
100. Glaser B, Cerasi E. Early intensive insulin treatment for induction of long-term glycaemic control in Type 2 diabetes. Diabetes Obes. Metab. 1(2), 67-74 (1999).
101. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with Type 2 diabetes: a randomized controlled trial. Diabetes Care 25(1), 89-94 (2002).
102. Dabiri G, JK, Krebs J et al. Benefits of rosiglitazone in children with T2DM. Diabetes (1904-P) (2005) (Abstract).
103. Schauer PR, Burguera B, Ikramuddin S et al. Effect of laparoscopic Roux-en Y gastric bypass on Type 2 diabetes mellitus. Ann. Surg. 238(4), 467-484; discussion 484-1465 (2003).
104. Inge TH, Miyano G, Bean J et al. Reversal of Type 2 diabetes mellitus and improvements in cardiovascular risk factors after surgical weight loss in adolescents. Pediatrics 123(1), 214-222 (2009).
105. White NH PL, Tamborlane WV, Geffner ME, Guandalini C. Clinical characteristics and co-morbidities in a large cohort of youth with Type 2 diabetes mellitus (T2DM) screened for the Treatment Options for Type 2 diabetes in Adolescents and Youth (TODAY) study. Diabetes (265-OR) (2009) (Abstract).
106. Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114(24), 2710-2738 (2006).
107. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343-1350 (2001).
108. Ettinger LM, Freeman K, DiMartino-Nardi JR, Flynn JT. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with Type 2 diabetes mellitus. J. Pediatr. 147(1), 67-73 (2005).
109. Fagot-Campagna A, Knowler WC, Pettitt D. Type 2 diabetes in Pima Indian children: cardiovascular risk factors at diagnosis and 10 years later. Diabetes 47(Suppl. 1), A155 (1998).
110. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset Type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 296(4), 421-426 (2006).
111. Yokoyama H, Okudaira M, Otani T et al. Higher incidence of diabetic nephropathy in Type 2 than in Type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 58(1), 302-311 (2000).
112. Yokoyama H, Okudaira M, Otani T et al. High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care 21(7), 1080-1085 (1998).
113. Bronson-Castain KW, Bearse MA Jr, Neuville J et al. Adolescents with Type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina 29(5), 618-626 (2009).
114. Pavkov ME, Sievers ML, Knowler WC, Bennett PH, Nelson RG. An explanation for the increase in heart disease mortality rates in diabetic Pima Indians: effect of renal replacement therapy. Diabetes Care 27(5), 1132-1136 (2004).
115. Gungor N, Thompson T, Sutton-Tyrrell K, Janosky J, Arslanian S. Early signs of cardiovascular disease in youth with obesity and Type 2 diabetes. Diabetes Care 28(5), 1219-1221 (2005).
116. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of Type 2 diabetes mellitus in children and adolescents. Lancet 369(9575), 1823-1831 (2007).
117. Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J. Pediatr. Gastroenterol. Nutr. 41(1), 94-98 (2005).
118. Papandreou D, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children. Clin. Nutr. 26(4), 409-415 (2007).
119. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30(6), 1356-1362 (1999).
120. Birmingham CL, Muller JL, Palepu A, Spinelli JJ, Anis AH. The cost of obesity in Canada. CMAJ 160(4), 483-488 (1999).
121. Johnson JA, Pohar SL, Majumdar SR. Health care use and costs in the decade after identification of Type 1 and Type 2 diabetes: a population-based study. Diabetes Care 29(11), 2403-2408 (2006).
122. Schubert CM, Sun SS, Burns TL, Morrison JA, Huang TT. Predictive ability of childhood metabolic components for adult metabolic syndrome and Type 2 diabetes. J. Pediatr. 155(3), S6 e1-e7 (2009).
123. Shah S, Kublaoui BM, Oden JD, White PC. Screening for Type 2 diabetes in obese youth. Pediatrics 124(2), 573-579 (2009).
124. Zeitler P, Epstein L, Grey M et al. Treatment options for Type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with Type 2 diabetes. Pediatr. Diabetes 8(2), 74-87 (2007).
125. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 368(9548), 1696-1705 (2006).